Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction

  • A Corrigendum to this article was published on 01 November 2006

Abstract

The engagement of programmed death 1 (PD-1) to its ligands, PD-L1 and PD-L21,2,3,4, inhibits proliferation and cytokine production mediated by antibodies to CD3 (refs. 5,6,7). Blocking the PD-1–PD-L1 pathway in mice chronically infected with lymphocytic choriomeningitis virus restores the capacity of exhausted CD8+ T cells to undergo proliferation, cytokine production and cytotoxic activity and, consequently, results in reduced viral load8. During chronic HIV infection, HIV-specific CD8+ T cells are functionally impaired9,10,11, showing a reduced capacity to produce cytokines and effector molecules as well as an impaired capacity to proliferate12,13,14,15. Here, we found that PD-1 was upregulated on HIV-specific CD8+ T cells; PD-1 expression levels were significantly correlated both with viral load and with the reduced capacity for cytokine production and proliferation of HIV-specific CD8+ T cells. Notably, cytomegalovirus (CMV)-specific CD8+ T cells from the same donors did not upregulate PD-1 and maintained the production of high levels of cytokines. Blocking PD-1 engagement to its ligand (PD-L1) enhanced the capacity of HIV-specific CD8+ T cells to survive and proliferate and led to an increased production of cytokines and cytotoxic molecules in response to cognate antigen. The accumulation of HIV-specific dysfunctional CD8+ T cells in the infected host could prevent the renewal of a functionally competent HIV-specific CD8+ repertoire.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: PD-1 is upregulated on HIV-specific CD8+ T cells.
Figure 2: Longitudinal analysis: PD-1 expression on HIV-specific CD8+ T cells correlates with viremia.
Figure 3: Pre-terminally differentiated phenotype and functional impairment of PD-1hi HIV-specific CD8+ T cells.
Figure 4: Blocking the PD-1–PD-L1 pathway increases effector molecules production and proliferation of HIV-specific CD8+ T cells.

References

  1. 1

    Chen, L. Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity. Nat. Rev. Immunol. 4, 336–347 (2004).

  2. 2

    Ishida, Y., Agata, Y., Shibahara, K. & Honjo, T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 11, 3887–3895 (1992).

  3. 3

    Agata, Y. et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int. Immunol. 8, 765–772 (1996).

  4. 4

    Latchman, Y. et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2, 261–268 (2001).

  5. 5

    Freeman, G.J. et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192, 1027–1034 (2000).

  6. 6

    Parry, R.V. et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol. Cell. Biol. 25, 9543–9553 (2005).

  7. 7

    Chemnitz, J.M., Parry, R.V., Nichols, K.E., June, C.H. & Riley, J.L. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J. Immunol. 173, 945–954 (2004).

  8. 8

    Barber, D.L. et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439, 682–687 (2006).

  9. 9

    Zajac, A.J. et al. Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 188, 2205–2213 (1998).

  10. 10

    Wherry, E.J., Barber, D.L., Kaech, S.M., Blattman, J.N. & Ahmed, R. Antigen-independent memory CD8 T cells do not develop during chronic viral infection. Proc. Natl. Acad. Sci. USA 101, 16004–16009 (2004).

  11. 11

    Pantaleo, G. & Koup, R.A. Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nat. Med. 10, 806–810 (2004).

  12. 12

    Wherry, E.J., Blattman, J.N. & Ahmed, R. Low CD8 T-cell proliferative potential and high viral load limit the effectiveness of therapeutic vaccination. J. Virol. 79, 8960–8968 (2005).

  13. 13

    Shankar, P. et al. Impaired function of circulating HIV-specific CD8+ T cells in chronic human immunodeficiency virus infection. Blood 96, 3094–3101 (2000).

  14. 14

    Migueles, S.A. et al. HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat. Immunol. 3, 1061–1068 (2002).

  15. 15

    Zhang, D. et al. Most antiviral CD8 T cells during chronic viral infection do not express high levels of perforin and are not directly cytotoxic. Blood 101, 226–235 (2003).

  16. 16

    Zhang, L. et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N. Engl. J. Med. 340, 1605–1613 (1999).

  17. 17

    Dornadula, G. et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. J. Am. Med. Assoc. 282, 1627–1632 (1999).

  18. 18

    Geels, M.J. et al. Identification of sequential viral escape mutants associated with altered T-cell responses in a human immunodeficiency virus type 1-infected individual. J. Virol. 77, 12430–12440 (2003).

  19. 19

    Price, D.A. et al. T cell receptor recognition motifs govern immune escape patterns in acute SIV infection. Immunity 21, 793–803 (2004).

  20. 20

    Champagne, P. et al. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature 410, 106–111 (2001).

  21. 21

    Appay, V. et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat. Med. 8, 379–385 (2002).

  22. 22

    Lichterfeld, M. et al. Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells. J. Exp. Med. 200, 701–712 (2004).

  23. 23

    Yang, O.O. et al. Decreased perforin and granzyme B expression in senescent HIV-1-specific cytotoxic T lymphocytes. Virology 332, 16–19 (2005).

  24. 24

    Lee, K.M. et al. Molecular basis of T cell inactivation by CTLA-4. Science 282, 2263–2266 (1998).

  25. 25

    Almanzar, G. et al. Long-term cytomegalovirus infection leads to significant changes in the composition of the CD8+ T-cell repertoire, which may be the basis for an imbalance in the cytokine production profile in elderly persons. J. Virol. 79, 3675–3683 (2005).

  26. 26

    Wherry, E.J., Blattman, J.N., Murali-Krishna, K., van der Most, R. & Ahmed, R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J. Virol. 77, 4911–4927 (2003).

  27. 27

    Altman, J.D. et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 274, 94–96 (1996).

  28. 28

    Younes, S.A. et al. HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity. J. Exp. Med. 198, 1909–1922 (2003).

  29. 29

    Douek, D.C. et al. A novel approach to the analysis of specificity, clonality, and frequency of HIV-specific T cell responses reveals a potential mechanism for control of viral escape. J. Immunol. 168, 3099–3104 (2002).

Download references

Acknowledgements

We thank P. Wilkinson, L. Greller and R. Somogyi for the statistical analyses and M. Lainesse for technical assistance. This work was supported by grants awarded to R.-P.S. from the US National Institutes of Health, the Canadian Institutes of Health Research, the Canadian Network for Vaccine and Immunotherapeutics, Genome Québec, Genome Canada and the Réseau SIDA FRSQ. R.-P.S. is the Canada Research Chair in Human Immunology. J.-P.R. is a scientific scholar receiving support from the Fonds de la Recherche en Santé du Québec (FRSQ). We also thank B. Walker, R. Koup and R. Ahmed for discussions.

Author information

L.T. did the experiments and wrote the paper. L.J., N.C., E.A.S. and S.G. gave previous help with the final experiments and with writing the paper. B.B. generated pMHC monomers. J.-P.R. and R.S.B. provided samples from research subjects. E.D. performed the viral sequencing. H.S. and R.S.B. developed the CBA cytotoxic kit. Co-senior authors E.K.H. and R.-P.S. supervised all experiments and wrote the paper.

Note: Supplementary information is available on the Nature Medicine website.

Correspondence to Rafick-Pierre Sekaly.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Fig. 1

Longitudinal analysis of PD-1 expression on HIV-specific CD8 T cells correlates with viremia. (PDF 577 kb)

Supplementary Fig. 2

Percentage of cytokine production of tetramer-positive cells is a function of levels of PD-1 expression. (PDF 590 kb)

Supplementary Fig. 3

Increased TNF-α production in HIV-specific CD8 T cells in a 6-d culture stimulation in the presence of anti-PD-L1 antibody. (PDF 733 kb)

Supplementary Table 1

Characteristics of participants with percentages of tetramer positive CD8+ T cells. (PDF 50 kb)

Supplementary Table 2

Phenotypic analysis of CMV-, EBV- and HIV-specific tetramer-positive cells in viremic and aviremic individuals. (PDF 40 kb)

Rights and permissions

Reprints and Permissions

About this article

Further reading